{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:03:37Z","timestamp":1786979017509,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":81,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319997155","type":"print"},{"value":"9783319997162","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-319-99716-2_12","type":"book-chapter","created":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T11:33:57Z","timestamp":1546169637000},"page":"249-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["CD30-Positive Lymphoproliferative Disorders"],"prefix":"10.1007","author":[{"given":"Liana","family":"Nikolaenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,31]]},"reference":[{"issue":"6","key":"12_CR1","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0889-8588(03)00117-5","volume":"17","author":"Rein Willemze","year":"2003","unstructured":"Willemze R, Meijer CJ (2003) Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am 17(1319\u20131332):vii\u2013viii","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","volume":"95","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vader PC et al (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653\u20133661","journal-title":"Blood"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768\u20133785","journal-title":"Blood"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","volume":"66","author":"H Stein","year":"1985","unstructured":"Stein H, Mason DY, Gerdes J et al (1985) The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848\u2013858","journal-title":"Blood"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","volume":"85","author":"B Falini","year":"1995","unstructured":"Falini B, Pileri S, Pizzolo G et al (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1\u201314","journal-title":"Blood"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/sj.jid.5700800","volume":"127","author":"C Assaf","year":"2007","unstructured":"Assaf C, Hirsch B, Wagner F et al (2007) Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol 127:1898\u20131904","journal-title":"J Invest Dermatol"},{"key":"12_CR7","unstructured":"Dupont A, Thulliez A (1956) Histio-monocytic reticulosis and mycosis fungoides; four case reports. Arch Belg Dermatol Syphiligr 12:263\u2013272"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/archderm.1968.01610070029004","volume":"97","author":"WL Macaulay","year":"1968","unstructured":"Macaulay WL (1968) Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign\u2013histologically malignant. Arch Dermatol 97:23\u201330","journal-title":"Arch Dermatol"},{"issue":"Suppl 1","key":"12_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.0303-6987.2006.00548.x","volume":"33","author":"W Kempf","year":"2006","unstructured":"Kempf W (2006) CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 33(Suppl 1):58\u201370","journal-title":"J Cutan Pathol"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000081485","volume":"210","author":"RM Pujol","year":"2005","unstructured":"Pujol RM, Muret MP, Bergua P, Bordes R, Alomar A (2005) Oral involvement in lymphomatoid papulosis. Report of two cases and review of the literature. Dermatology 210:53\u201357","journal-title":"Dermatology"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1046\/j.1365-2133.1999.03218.x","volume":"141","author":"JJ Scarisbrick","year":"1999","unstructured":"Scarisbrick JJ, Evans AV, Woolford AJ, Black MM, Russell-Jones R (1999) Regional lymphomatoid papulosis: a report of four cases. Br J Dermatol 141:1125\u20131128","journal-title":"Br J Dermatol"},{"key":"12_CR12","first-page":"574","volume":"24","author":"C Querfeld","year":"2010","unstructured":"Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM (2010) Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park). 24:574\u2013587","journal-title":"Oncology (Williston Park)."},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40257-016-0192-6","volume":"17","author":"I Wieser","year":"2016","unstructured":"Wieser I, Wohlmuth C, Nunez CA, Duvic M (2016) Lymphomatoid papulosis in children and adolescents: a systematic review. Am J Clin Dermatol 17:319\u2013327","journal-title":"Am J Clin Dermatol"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.hoc.2016.11.006","volume":"31","author":"MB Sauder","year":"2017","unstructured":"Sauder MB, O\u2019Malley JT, LeBoeuf NR (2017) CD30+ lymphoproliferative disorders of the skin. Hematol Oncol Clin North Am 31:317\u2013334","journal-title":"Hematol Oncol Clin North Am"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1634\/theoncologist.2015-0242","volume":"21","author":"N Cordel","year":"2016","unstructured":"Cordel N, Tressieres B, D\u2019Incan M et al (2016) Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis. Oncologist 21:76\u201383","journal-title":"Oncologist"},{"key":"12_CR16","first-page":"767","volume":"14","author":"I Wieser","year":"2016","unstructured":"Wieser I, Tetzlaff MT, Torres Cabala CA, Duvic M (2016) Primary cutaneous CD30(+) lymphoproliferative disorders. J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG 14:767\u2013782","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10024-004-8087-6","volume":"8","author":"S Kumar","year":"2005","unstructured":"Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES (2005) Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 8:52\u201360","journal-title":"Pediatr Dev Pathol"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","volume":"49","author":"HL Liu","year":"2003","unstructured":"Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH (2003) CD30+ cutaneous lymphoproliferative disorders: the stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49:1049\u20131058","journal-title":"J Am Acad Dermatol"},{"key":"12_CR19","first-page":"331","volume":"10","author":"N Booken","year":"2012","unstructured":"Booken N, Goerdt S, Klemke CD (2012) Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the mannheim cutaneous lymphoma registry. J der Dtschn Dermatol Ges = J Ger Soc Dermatol JDDG 10:331\u2013339","journal-title":"J der Dtschn Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/archdermatol.2009.74","volume":"145","author":"DK Woo","year":"2009","unstructured":"Woo DK, Jones CR, Vanoli-Storz MN et al (2009) Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol 145:667\u2013674","journal-title":"Arch Dermatol"},{"key":"12_CR21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/archdermatol.2009.280","volume":"145","author":"MF Benner","year":"2009","unstructured":"Benner MF, Willemze R (2009) Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 145:1399\u20131404","journal-title":"Arch Dermatol"},{"key":"12_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.semdp.2016.11.005","volume":"34","author":"W Kempf","year":"2017","unstructured":"Kempf W (2017) A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol 34:22\u201335","journal-title":"Semin Diagn Pathol"},{"key":"12_CR23","first-page":"441","volume":"140","author":"L Shabrawi-Caelen El","year":"2004","unstructured":"El Shabrawi-Caelen L, Kerl H, Cerroni L (2004) Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 140:441\u2013447","journal-title":"Arch Dermatol"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/PAS.0b013e3181e75356","volume":"34","author":"A Saggini","year":"2010","unstructured":"Saggini A, Gulia A, Argenyi Z et al (2010) A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+\u2009cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 34:1168\u20131175","journal-title":"Am J Surg Pathol"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000355479","volume":"227","author":"W Kempf","year":"2013","unstructured":"Kempf W, Kazakov DV, Paredes BE, Laeng HR, Palmedo G, Kutzner H (2013) Primary cutaneous anaplastic large cell lymphoma with angioinvasive features and cytotoxic phenotype: a rare lymphoma variant within the spectrum of CD30+ lymphoproliferative disorders. Dermatology 227:346\u2013352","journal-title":"Dermatology"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jaad.2012.12.952","volume":"68","author":"W Kempf","year":"2013","unstructured":"Kempf W, Kazakov DV, Baumgartner HP, Kutzner H (2013) Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings. J Am Acad Dermatol 68:809\u2013816","journal-title":"J Am Acad Dermatol"},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00000478-199504000-00002","volume":"19","author":"KP Mann","year":"1995","unstructured":"Mann KP, Hall B, Kamino H, Borowitz MJ, Ratech H (1995) Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol 19:407\u2013416","journal-title":"Am J Surg Pathol"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.0303-6987.2004.00204.x","volume":"31","author":"JH Lin","year":"2004","unstructured":"Lin JH, Lee JY (2004) Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia. J Cutan Pathol 31:458\u2013461","journal-title":"J Cutan Pathol"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1046\/j.1365-2559.2001.01271.x","volume":"39","author":"J Wang","year":"2001","unstructured":"Wang J, Sun NC, Nozawa Y et al (2001) Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features. Histopathology 39:476\u2013481","journal-title":"Histopathology"},{"key":"12_CR31","first-page":"1893","volume":"150","author":"RE Felgar","year":"1997","unstructured":"Felgar RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE (1997) TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 150:1893\u20131900","journal-title":"Am J Pathol"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","volume":"96","author":"H Stein","year":"2000","unstructured":"Stein H, Foss HD, Durkop H et al (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681\u20133695","journal-title":"Blood"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2133.2009.09147.x","volume":"161","author":"MF Benner","year":"2009","unstructured":"Benner MF, Jansen PM, Meijer CJ, Willemze R (2009) Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 161:121\u2013127","journal-title":"Br J Dermatol"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.0906-6705.2005.00293.x","volume":"14","author":"J Greisser","year":"2005","unstructured":"Greisser J, Doebbeling U, Roos M et al (2005) Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol 14:380\u2013385","journal-title":"Exp Dermatol"},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/jid.2009.299","volume":"130","author":"FK Braun","year":"2010","unstructured":"Braun FK, Hirsch B, Al-Yacoub N et al (2010) Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol 130:826\u2013840","journal-title":"J Invest Dermatol"},{"issue":"1327","key":"12_CR36","first-page":"e1","volume":"67","author":"N Stutz","year":"2012","unstructured":"Stutz N, Johnson RD, Wood GS (2012) The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol 67(1327):e1\u2013e10","journal-title":"J Am Acad Dermatol"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/gcc.10184","volume":"37","author":"X Mao","year":"2003","unstructured":"Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker S (2003) Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 37:176\u2013185","journal-title":"Genes Chromosomes Cancer"},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/jid.2009.270","volume":"130","author":"MS Kester van","year":"2010","unstructured":"van Kester MS, Tensen CP, Vermeer MH et al (2010) Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol 130:563\u2013575","journal-title":"J Invest Dermatol"},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/PAS.0b013e318282d01e","volume":"37","author":"LJ Karai","year":"2013","unstructured":"Karai LJ, Kadin ME, Hsi ED et al (2013) Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol 37:1173\u20131181","journal-title":"Am J Surg Pathol"},{"key":"12_CR40","unstructured":"Swerdlow S, Campo E, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues 4th edn."},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/PAP.0000000000000047","volume":"22","author":"X Xing","year":"2015","unstructured":"Xing X, Feldman AL (2015) Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol 22:29\u201349","journal-title":"Adv Anat Pathol"},{"key":"12_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/DAD.0000000000000377","volume":"37","author":"D Gratzinger","year":"2015","unstructured":"Gratzinger D, Million L, Kim YH (2015) Occult dermal lymphatic involvement is frequent in primary cutaneous anaplastic large cell lymphoma. Am J Dermatopathol 37:767\u2013770","journal-title":"Am J Dermatopathol"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1001\/archderm.1995.01690230059010","volume":"131","author":"RL Kerschmann","year":"1995","unstructured":"Kerschmann RL, Berger TG, Weiss LM et al (1995) Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage. Arch Dermatol 131:1281\u20131288","journal-title":"Arch Dermatol"},{"key":"12_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/1066896915568993","volume":"23","author":"D Xue","year":"2015","unstructured":"Xue D, Li X, Ren Y, Liu Q, Yen Y, Xue L (2015) Primary cutaneous anaplastic large cell lymphoma with positive ALK expression and a rapidly progressive cutaneous nodule. Int J Surg Pathol 23:333\u2013335","journal-title":"Int J Surg Pathol"},{"key":"12_CR45","first-page":"59","volume":"7","author":"TK Uzuncakmak","year":"2017","unstructured":"Uzuncakmak TK, Akdeniz N, Karadag AS, Taskin S, Zemheri EI, Argenziano G (2017) Primary cutaneous CD30(+) ALK(-) anaplastic large cell lymphoma with dermoscopic findings: a case report. Dermatol Prac Concept 7:59\u201361","journal-title":"Dermatol Prac Concept"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/cup.12719","volume":"43","author":"A Souza De","year":"2016","unstructured":"De Souza A, Tinguely M, Burghart DR, Berisha A, Mertz KD, Kempf W (2016) Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages. J Cutan Pathol 43:579\u2013588","journal-title":"J Cutan Pathol"},{"key":"12_CR47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1525-1470.1996.tb00734.x","volume":"13","author":"MA Paul","year":"1996","unstructured":"Paul MA, Krowchuk DP, Hitchcock MG, Jorizzo JL (1996) Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol 13:501\u2013506","journal-title":"Pediatr Dermatol"},{"key":"12_CR48","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","volume":"118","author":"W Kempf","year":"2011","unstructured":"Kempf W, Pfaltz K, Vermeer MH et al (2011) EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118:4024\u20134035","journal-title":"Blood"},{"key":"12_CR49","first-page":"3194738","volume":"2017","author":"A Bilgic Temel","year":"2017","unstructured":"Bilgic Temel A, Unal B, Erdi Sanli H, Duygulu S, Uzun S (2017) A severe case of lymphomatoid papulosis type E successfully treated with interferon-alfa 2a. Case Rep Dermatol Med 2017:3194738","journal-title":"Case Rep Dermatol Med"},{"key":"12_CR50","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0190-9622(87)70248-5","volume":"17","author":"K Thomsen","year":"1987","unstructured":"Thomsen K, Wantzin GL (1987) Lymphomatoid papulosis. A follow-up study of 30 patients. J Am Acad Dermatol 17:632\u2013636","journal-title":"J Am Acad Dermatol"},{"key":"12_CR51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1365-2133.1982.tb00529.x","volume":"107","author":"GL Wantzin","year":"1982","unstructured":"Wantzin GL, Thomsen K (1982) PUVA-treatment in lymphomatoid papulosis. Br J Dermatol 107:687\u2013690","journal-title":"Br J Dermatol"},{"key":"12_CR52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2340\/00015555644651","volume":"64","author":"G Lange-Wantzin","year":"1984","unstructured":"Lange-Wantzin G, Thomsen K, Hou-Jensen K (1984) Lymphomatoid papulosis: a follow-up study. Acta Derm Venereol 64:46\u201351","journal-title":"Acta Derm Venereol"},{"key":"12_CR53","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/archderm.1995.01690210126030","volume":"131","author":"M Volkenandt","year":"1995","unstructured":"Volkenandt M, Kerscher M, Sander C, Meurer M, Rocken M (1995) PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. Arch Dermatol 131:1094","journal-title":"Arch Dermatol"},{"key":"12_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/0019-5154.108109","volume":"58","author":"E Errichetti","year":"2013","unstructured":"Errichetti E, Piccirillo A, Ricciuti F, Ricciuti F (2013) Steroid-resistant localized lymphomatoid papulosis treated with local bath-PUVA therapy. Indian J Dermatol 58:163","journal-title":"Indian J Dermatol"},{"key":"12_CR55","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/bjd.13920","volume":"173","author":"MS Bruijn","year":"2015","unstructured":"Bruijn MS, Horvath B, van Voorst Vader PC, Willemze R, Vermeer MH (2015) Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch cutaneous lymphoma group. Br J Dermatol 173:1319\u20131322","journal-title":"Br J Dermatol"},{"key":"12_CR56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0190-9622(96)90442-9","volume":"34","author":"EC Vonderheid","year":"1996","unstructured":"Vonderheid EC, Sajjadian A, Kadin ME (1996) Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 34:470\u2013481","journal-title":"J Am Acad Dermatol"},{"key":"12_CR57","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R (2015) Results of a phase II trial of brentuximab vedotin for CD30+ Cutaneous T-Cell lymphoma and lymphomatoid papulosis. J Clin Oncol 33:3759\u20133765","journal-title":"J Clin Oncol"},{"key":"12_CR58","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/j.1365-2133.2004.05993.x","volume":"150","author":"B Didona","year":"2004","unstructured":"Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R (2004) Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 150:1198\u20131201","journal-title":"Br J Dermatol"},{"key":"12_CR59","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.leukres.2011.06.029","volume":"35","author":"A Oliveira","year":"2011","unstructured":"Oliveira A, Fernandes I, Alves R, Lima M, Selores M (2011) Primary cutaneous CD30 positive anaplastic large cell lymphoma\u2013report of a case treated with bexarotene. Leuk Res 35:e190\u2013e192","journal-title":"Leuk Res"},{"key":"12_CR60","first-page":"216","volume":"6","author":"M Ardigo","year":"2007","unstructured":"Ardigo M, Marulli GC, Cota C, Mastroianni A, Berardesca E (2007) Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement. J Drugs Dermatol JDD 6:216\u2013219","journal-title":"J Drugs Dermatol JDD"},{"key":"12_CR61","first-page":"404","volume":"109","author":"B Qiu","year":"1996","unstructured":"Qiu B, Chen M (1996) Treatment of cutaneous T cell lymphoma with low doses of interferon alpha-2b. Chin Med J (Engl) 109:404\u2013406","journal-title":"Chin Med J (Engl)"},{"key":"12_CR62","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2340\/00015555-1692","volume":"94","author":"I Yokoi","year":"2014","unstructured":"Yokoi I, Ishikawa E, Koura A et al (2014) Successful treatment of primary cutaneous anaplastic large cell lymphoma with intralesional methotrexate therapy. Acta Derm Venereol 94:319\u2013320","journal-title":"Acta Derm Venereol"},{"key":"12_CR63","unstructured":"Querfeld C, Kuzel TM, Guitart J, Rosen ST (2007) Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncol 21:689\u2013696; discussion 99\u2013700 (Williston Park)"},{"key":"12_CR64","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","volume":"20","author":"EC Vonderheid","year":"1989","unstructured":"Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ (1989) Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 20:416\u2013428","journal-title":"J Am Acad Dermatol"},{"key":"12_CR65","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/1097-0142(19930315)71:6<2097::AID-CNCR2820710626>3.0.CO;2-7","volume":"71","author":"RC Beljaards","year":"1993","unstructured":"Beljaards RC, Kaudewitz P, Berti E et al (1993) Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients. Cancer 71:2097\u20132104","journal-title":"Cancer"},{"key":"12_CR66","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.ijrobp.2007.08.077","volume":"70","author":"JB Yu","year":"2008","unstructured":"Yu JB, McNiff JM, Lund MW, Wilson LD (2008) Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys 70:1542\u20131545","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12_CR67","doi-asserted-by":"publisher","first-page":"629587","DOI":"10.1155\/2015\/629587","volume":"2015","author":"MS Gentile","year":"2015","unstructured":"Gentile MS, Martinez-Escala ME, Thomas TO et al (2015) Single-fraction radiotherapy for CD30(+) lymphoproliferative disorders. Biomed Res Int 2015:629587","journal-title":"Biomed Res Int"},{"key":"12_CR68","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","volume":"119","author":"SM Horwitz","year":"2012","unstructured":"Horwitz SM, Kim YH, Foss F et al (2012) Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119:4115\u20134122","journal-title":"Blood"},{"key":"12_CR69","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000068451","volume":"206","author":"RA Krathen","year":"2003","unstructured":"Krathen RA, Ward S, Duvic M (2003) Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 206:142\u2013147","journal-title":"Dermatology"},{"key":"12_CR70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000324185","volume":"3","author":"I Cervigon-Gonzalez","year":"2011","unstructured":"Cervigon-Gonzalez I, Torres-Iglesias LM, Palomo-Arellano A, Gil-Pascual B (2011) Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox. Case Rep Dermatol 3:13\u201317","journal-title":"Case Rep Dermatol"},{"key":"12_CR71","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/bjd.12042","volume":"168","author":"JJ Scarisbrick","year":"2013","unstructured":"Scarisbrick JJ, Morris S, Azurdia R et al (2013) U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 168:192\u2013200","journal-title":"Br J Dermatol"},{"key":"12_CR72","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1067\/mjd.2001.117519","volume":"45","author":"LE French","year":"2001","unstructured":"French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH (2001) Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 45:914\u2013918","journal-title":"J Am Acad Dermatol"},{"key":"12_CR73","doi-asserted-by":"crossref","unstructured":"Kim YH, Whittaker S, Horwitz SM et al (2016) Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician\u2019s choice (Methotrexate or Bexarotene): the phase 3 alcanza study. Am Soc Hematology, 2016","DOI":"10.1182\/blood.V128.22.182.182"},{"key":"12_CR74","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","volume":"7","author":"M Duvic","year":"2006","unstructured":"Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N (2006) Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 7:51\u201358","journal-title":"Clin Lymphoma Myeloma"},{"key":"12_CR75","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2133.1992.tb14853.x","volume":"127","author":"JU Rijlaarsdam","year":"1992","unstructured":"Rijlaarsdam JU, Huijgens PC, Beljaards RC, Bakels V, Willemze R (1992) Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol 127:524\u2013528","journal-title":"Br J Dermatol"},{"key":"12_CR76","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1600-0560.2006.00488.x","volume":"33","author":"L Boudova","year":"2006","unstructured":"Boudova L, Kazakov DV, Jindra P et al (2006) Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56\u2009+\u2009anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. J Cutan Pathol 33:584\u2013589","journal-title":"J Cutan Pathol"},{"key":"12_CR77","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1365-4362.2003.01801.x","volume":"42","author":"JJ Wu","year":"2003","unstructured":"Wu JJ, Guitart J, Tucker RM, Kuzel TM, Rosen ST (2003) Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission. Int J Dermatol 42:464\u2013465","journal-title":"Int J Dermatol"},{"key":"12_CR78","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","volume":"86","author":"G Akpek","year":"1999","unstructured":"Akpek G, Koh HK, Bogen S, O\u2019Hara C, Foss FM (1999) Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 86:1368\u20131376","journal-title":"Cancer"},{"key":"12_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3315\/jdcr.2008.1013","volume":"2","author":"MP Chao-Lo","year":"2008","unstructured":"Chao-Lo MP, King-Ismael D, Lopez RA (2008) Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep 2:31\u201334","journal-title":"J Dermatol Case Rep"},{"key":"12_CR80","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/cup.12547","volume":"42","author":"U Wehkamp","year":"2015","unstructured":"Wehkamp U, Oschlies I, Nagel I et al (2015) ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. J Cutan Pathol 42:870\u2013877","journal-title":"J Cutan Pathol"},{"key":"12_CR81","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/0190-9622(92)70111-R","volume":"26","author":"F Meier","year":"1992","unstructured":"Meier F, Schaumburg-Lever G, Kaiserling E, Scheel-Walter HG, Scherwitz C (1992) Primary cutaneous large-cell anaplastic (Ki-1) lymphoma in a child. J Am Acad Dermatol 26:813\u2013817","journal-title":"J Am Acad Dermatol"}],"container-title":["Cancer Treatment and Research","T-Cell and NK-Cell Lymphomas"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-99716-2_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T11:09:53Z","timestamp":1694516993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-99716-2_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,31]]},"ISBN":["9783319997155","9783319997162"],"references-count":81,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-99716-2_12","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,31]]}}}